6th Jan 2021 18:17
RTW Venture Fund Ltd - New York-based investment company focussed on life sciences, biopharmaceutical, and medical technology companies- Participates in the USD56 million Series A financing round of Biomea Fusion Inc.
Biomea is an oncology company which develops medicines targeting specific cancer-driving mutations. It plans to use the funds raised to advance the development of its portfolio of irreversible inhibitors, including an irreversible inhibitor of menin, a newly-recognized onco-target found in several forms of liquid and solid tumors.
RTW Venture did not disclose the size of its investment.
Current stock price: USD2.10
Year-to-date change: up 12%
By Ife Taiwo; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Rtw Biotech